Publications by authors named "Peter Piliero"

Claim this Profile
B
Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial.
Mabrouk M Elgadi, Peter J Piliero

Drugs R D· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Susceptibility of HIV-1 to tipranavir and other antiretroviral agents in treatment-experienced patients: The UTILIZE Study.
John D Baxter, Laveeza Bhatti, Eoin Coakley, Jennifer Bartczak, Marita McDonough, Peter J Piliero

Curr HIV Res· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.
R Douglas Bruce, Frederick L Altice, David E Moody, Shen-Nan Lin, Wenfang B Fang, Peter J Piliero

Drug Alcohol Depend· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis.
Anna Maria Cammett, Thomas R MacGregor, Jan M Wruck, Franco Felizarta, Patrick Miailhes, Peter J Piliero

Antimicrob Agents Chemother· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.
Anita A Mathias, John Hinkle, Gong Shen, Jeff Enejosa, Peter J Piliero

J Acquir Immune Defic Syndr· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients.
Michael Sension, Peter J Piliero

J Assoc Nurses AIDS Care· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.
Joseph C Gathe, Gerald Pierone, Peter Piliero, Keikawus Arasteh, Rafael Rubio

AIDS Res Hum Retroviruses· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
Edwin DeJesus, Peter J Piliero, Kim Summers, Mary Beth Wire, Daniel S Stein

Antimicrob Agents Chemother· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.
Melanie Thompson, Edwin DeJesus, Gary Richmond, David Wheeler, John Flaherty, Peter Piliero

AIDS· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Mark Nelson, Keikawus Arastéh, Bonaventura Clotet, David A Cooper, Keith Henry, Peter J Piliero

J Acquir Immune Defic Syndr· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.
Benoit Trottier, Sharon Walmsley, Jacques Reynes, Peter Piliero, Mary O'Hearn

J Acquir Immune Defic Syndr· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.
Jacob Lalezari, Melanie Thompson, Priny Kumar, Peter Piliero, Richard Davey

AIDS· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Appropriate use of nevirapine for long-term therapy.
Jonathan Leith, Peter Piliero, Stephen Storfer, Douglas Mayers, Ralf Hinzmann

J Infect Dis· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies for initiating combination antiretroviral therapy.
Michael L Tapper, Eric S Daar, Peter J Piliero, Kimberly Smith, Corklin Steinhart

AIDS Patient Care STDS· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An assessment of herbal therapy use, adherence and utilization of pharmacy services in HIV clinics.
John J Faragon, Bonnie D Purdy, Peter J Piliero

J Herb Pharmacother· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.
Pedro E Cahn, José M Gatell, Kathleen Squires, Lisa D Percival, Peter J Piliero

J Int Assoc Physicians AIDS Care (Chic)· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developments in HIV treatments: strategies for success.
Peter Piliero

AIDS Read· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atazanavir: A novel once-daily protease inhibitor.
Peter J Piliero

Drugs Today (Barc)· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
Peter J Piliero

J Acquir Immune Defic Syndr· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.
Mary Beth Wire, Charles Ballow, Sandra L Preston, Craig W Hendrix, Peter J Piliero

AIDS· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Buffalo hump: what the experts suggest.
Peter J Piliero, Grace A McComsey

AIDS Clin Care· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diaphragmatic paralysis due to isolated phrenic neuropathy in an HIV-infected man.
Peter J Piliero, Lydia Estanislao, David Simpson

Neurology· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs.
John J Faragon, Peter J Piliero

AIDS Read· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics and clinical use of anti-HIV drugs.
Sandra L Preston, Peter J Piliero, George L Drusano

Infect Dis Clin North Am· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of lipid elevations associated with the treatment of patients with HIV infection.
Peter J Piliero

MedGenMed· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis